TransMedics Group Statistics
Want to see TMDX full AI Analyst Report?
TransMedics Group (TMDX) Stock Statistics & Valuation Metrics
Total Valuation
TransMedics Group has a market cap or net worth of $3.16B. The enterprise value is $3.78B.
- Market Cap
- $3.16B
- Enterprise Value
- $3.78B
Share Statistics
TransMedics Group has 34,733,883 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 34,733,883
- Owned by Insiders
- 3.61%
- Owned by Institutions
- 76.08%
Financial Efficiency
TransMedics Group’s return on equity (ROE) is 0.40 and return on invested capital (ROIC) is 10.94%.
- Return on Equity (ROE)
- 0.40
- Return on Assets (ROA)
- 0.18
- Return on Invested Capital (ROIC)
- 10.94%
- Return on Capital Employed (ROCE)
- 0.11
- Revenue Per Employee
- 674.27K
- Profits Per Employee
- 211.91K
- Employee Count
- 898
- Asset Turnover
- 0.57
- Inventory Turnover
- 4.96
Valuation Ratios
The current PE Ratio of TransMedics Group is 21.91. TransMedics Group’s PEG ratio is 0.39.
- PE Ratio
- 21.91
- PS Ratio
- 4.39
- PB Ratio
- 5.80
- Price to FCF
- 71.50
- Price to Operating Cash Flow
- 28.41
- PEG Ratio
- 0.39
Income Statement
In the last 12 months, TransMedics Group had revenue of 605.49M and earned 190.29M in profits. Earnings per share was 5.60.
- Revenue
- 605.49M
- Gross Profit
- 362.81M
- Operating Income
- 108.58M
- Pretax Income
- 107.52M
- Net Income
- 190.29M
- EBITDA
- 148.49M
- Earnings Per Share (EPS)
- 5.60
Cash Flow
In the last 12 months, operating cash flow was 112.36M and capital expenditures -67.66M, giving a free cash flow of 44.70M billion.
- Operating Cash Flow
- 112.36M
- Free Cash Flow
- 44.70M
- Free Cash Flow per Share
- 1.29
Dividends & Yields
TransMedics Group pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 1.40%
- Earnings Yield
- 4.53%
Stock Price Statistics
- Beta
- 0.72
- 52-Week Price Change
- -24.67%
- 50-Day Moving Average
- 79.64
- 200-Day Moving Average
- 91.97
- Relative Strength Index (RSI)
- 67.00
- Average Volume (3m)
- 887.53K
Important Dates
TransMedics Group upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 02, 2027
- Ex-Dividend Date
- ―
Financial Position
TransMedics Group as a current ratio of 7.14, with Debt / Equity ratio of 99.28%
- Current Ratio
- 7.14
- Quick Ratio
- 6.59
- Debt to Market Cap
- 0.11
- Net Debt to EBITDA
- -0.13
- Interest Coverage Ratio
- 7.88
Taxes
In the past 12 months, TransMedics Group has paid -82.77M in taxes.
- Income Tax
- -82.77M
- Effective Tax Rate
- -0.77
Enterprise Valuation
TransMedics Group EV to EBITDA ratio is 25.67, with an EV/FCF ratio of 79.87.
- EV to Sales
- 4.91
- EV to EBITDA
- 25.67
- EV to Free Cash Flow
- 79.87
- EV to Operating Cash Flow
- 31.77
Balance Sheet
TransMedics Group has $492.96M in cash and marketable securities with $866.90M in debt, giving a net cash position of -$373.94M billion.
- Cash & Marketable Securities
- $492.96M
- Total Debt
- $866.90M
- Net Cash
- -$373.94M
- Net Cash Per Share
- -$10.77
- Tangible Book Value Per Share
- $15.27
Margins
Gross margin is 58.60%, with operating margin of 11.88%, and net profit margin of 19.85%.
- Gross Margin
- 58.60%
- Operating Margin
- 11.88%
- Pretax Margin
- 10.12%
- Net Profit Margin
- 19.85%
- EBITDA Margin
- 19.11%
- EBIT Margin
- 13.56%
Analyst Forecast
The average price target for TransMedics Group is $102.89, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $102.89
- Price Target Upside
- 11.82% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 11
- Revenue Growth Forecast
- 28.48%
- EPS Growth Forecast
- 55.43%
Scores
- Smart Score
- 7
- AI Score
- 65
